Government response to ACMD advice on remimazolam (accessible)
Published 2 March 2023
© Crown copyright 2023
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/response-to-the-acmds-report-on-remimazolam-byfavo/government-response-to-acmd-advice-on-remimazolam-accessible
From:
Rt Hon Chris Philp MP
Minister of State for Crime, Policing and Fire
2 Marsham Street
London
SW1P 4DF
To:
Professor Owen Bowden-Jones,
Chair, Advisory Council on the Misuse of Drugs (ACMD)
Professor Roger Knaggs,
Chair of Technical Committee, ACMD
C/o 1st Floor,
Peel Building
2 Marsham Street
London
SW1P 4DF
By email: acmd@homeoffice.gov.uk
2 March 2023
Dear Owen and Roger,
I am grateful to the ACMD for their advice on remimazolam (or ‘Byfavo’). I have set out each recommendation and the government’s response below.
Recommendation 1
The ACMD recommends that remimazolam should be controlled as a Class C drug under the Misuse of Drugs Act 1971.
Government response
The government accepts this recommendation and will implement it when Parliamentary time allows.
Recommendation 2
The ACMD recommends that remimazolam should be scheduled under Schedule 4 (Part 1) of the Misuse of Drugs Regulations 2001.
Government response
The government accepts this recommendation and will implement it when Parliamentary time allows.
Thank you again for your advice.
Rt Hon Chris Philp MP
Minister of State for Crime, Policing and Fire